Monte Rosa Therapeutics (GLUE) AI Stock Analysis

• Market Cap: $1.29B
• Dividend Yield: N/A
• Average Volume (3M): 945.85K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.78
• Revenue Growth: 1112.27%
• EPS Growth: N/A
• Country: US
• Employees: 142
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 80,015,670
• 10 Day Avg. Volume: 849,224
• 30 Day Avg. Volume: 945,852
• PEG Ratio: 0.64
• Price to Book (P/B): 5.59
• Price to Sales (P/S): 10.53
• P/FCF Ratio: -47.37
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: 7.72
• Enterprise Value/Gross Profit: 7.99
• Enterprise Value/Ebitda: -20.83
• 1Y Price Target: $32.33
• Price Target Upside: 105.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -1.52
• Revenue Forecast (FY): $56.77M

• Rating: 54 Neutral
• Price Target: $16.50 ▲(4.70% Upside)
• Action: Downgraded Date: 03/17/26
• Date: Action: Downgraded 03/17/26

The score is held back primarily by weak financial performance (continued losses, 2025 revenue decline, and renewed cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting these are supportive corporate events—strong financing that extends runway and encouraging Phase 1 MRT-8102 results—while valuation provides limited support due to a negative P/E and no dividend.

Positive Factors

Extended Cash Runway

A multi-year cash runway materially reduces near-term financing pressure and allows Monte Rosa to fund multiple Phase 2 initiations and ancillary development activities. This runway supports disciplined execution across programs, lowering dilution risk while enabling planned value-inflection milestones over the next several years.

Positive MRT-8102 Phase 1 Data

Robust biomarker suppression and clean safety in Phase 1 validate the QuEEN molecular glue approach and de‑risk MRT-8102's mechanism. Durable biomarker efficacy across cohorts supports broader development in NLRP3/IL‑1/IL‑6 inflammatory indications and strengthens the platform's scientific credibility with long-term pipeline implications.

Strategic Partnership

A supply agreement with a major pharma validates MRT-2359's clinical strategy and provides operational leverage for an efficient Phase 2. Partner support for combination studies enhances trial design, preserves company cash for other programs, and signals external confidence in the oncology degrader franchise.

Negative Factors

Revenue Decline & Losses

A sharp revenue decline coupled with ongoing operating losses constrains internal ability to fund development long-term without external capital. Persistent negative EBIT limits reinvestment capacity and means strategic progress will remain linked to milestone-dependent partnership economics and financing outcomes.

Volatile Cash Generation

Intermittent positive cash flow followed by a reversal to meaningful burn highlights execution and timing risk in R&D spending and revenue recognition. This volatility complicates multi-year planning and preserves the structural need to manage burn closely even with extended runway.

Clinical-Stage Revenue Model

As a clinical‑stage biotech without product sales, Monte Rosa's revenue depends on collaborations, upfronts, and milestones, which are lumpy and contingent on clinical success. Structural dependency on partner deals and future commercialization outcomes increases execution and revenue realization risk over coming quarters.

Monte Rosa Therapeutics Business Overview & Revenue Model

Company Description

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Monte Rosa Therapeutics does not primarily rely on product sales because it is a clinical-stage company and, to the extent publicly disclosed, does not have commercialized products generating material recurring product revenue. Instead, its revenue is primarily derived from (a) collaboration and partnership arrangements with larger pharmaceutical companies, which can include upfront payments, research funding/reimbursement, and development/regulatory/sales-based milestone payments, and (b) potential royalties on net sales of partnered products if any partnered candidates reach commercialization. In periods where collaboration agreements are active, the company may recognize revenue as it performs R&D services or satisfies performance obligations under the agreements. If specific active partners, payment amounts, or the split between upfront, milestone, and reimbursement revenue is not available from the provided context, those details are null.

Monte Rosa Therapeutics Financial Statement Overview

Summary

Mixed fundamentals: a solid balance sheet (72) and improving loss trajectory are offset by a 2025 revenue decline and continued operating losses (income statement 34) plus a swing back to operating and free cash flow burn in 2025 (cash flow 45).

Income Statement

The company has built a meaningful revenue base in recent years (2024: $75.6M; 2025: $123.7M), but growth turned negative in 2025 (revenue down ~31.9% vs. prior year). Profitability remains weak with continued operating losses (2025 EBIT: -$54.2M; net loss: -$38.6M), even though losses improved materially versus 2024 (net loss: -$72.7M). Overall, improving loss trajectory is a positive, but the 2025 revenue decline and persistent losses keep the income statement score restrained.

Balance Sheet

The balance sheet looks relatively solid for a biotech: equity is sizable and increasing (2025 equity: $233.1M vs. 2024: $222.9M) alongside a growing asset base (2025 assets: $448.7M). Leverage appears manageable with debt of $39.2M in 2025, and prior-year debt-to-equity was low (~0.19 in 2024 and ~0.26 in 2023). The key weakness is that ongoing losses translate into negative returns on equity (e.g., 2024 return on equity around -0.33), which could pressure capital over time if cash burn persists.

Cash Flow

Cash generation has been volatile. 2024 showed positive cash flow (operating cash flow: +$42.0M; free cash flow: +$38.0M), but 2025 swung back to cash burn (operating cash flow: -$22.8M; free cash flow: -$27.5M) and free cash flow growth was sharply negative. While the company has demonstrated it can produce positive cash flow in some periods, the recent reversal signals elevated funding and execution risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	123.67M	75.62M	0.00	0.00	0.00
Gross Profit	115.32M	67.50M	-6.22M	-8.56M	0.00
EBITDA	-45.85M	-72.99M	-137.09M	-108.64M	-70.75M
Net Income	-38.63M	-72.70M	-135.35M	-108.50M	-73.96M
Balance Sheet
Total Assets	448.66M	438.73M	303.75M	342.39M	366.33M
Cash, Cash Equivalents and Short-Term Investments	377.10M	372.15M	232.41M	262.83M	346.07M
Total Debt	39.19M	42.72M	46.04M	47.00M	0.00
Total Liabilities	215.60M	215.80M	124.50M	70.98M	18.81M
Stockholders Equity	233.06M	222.94M	179.25M	271.41M	347.51M
Cash Flow
Free Cash Flow	-27.50M	38.01M	-62.84M	-105.38M	-69.09M
Operating Cash Flow	-22.80M	42.00M	-43.80M	-92.47M	-59.36M
Investing Cash Flow	-101.83M	-44.45M	88.80M	-219.22M	-9.65M
Financing Cash Flow	30.35M	98.89M	27.49M	20.47M	377.56M

Monte Rosa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLUE, the sentiment is Negative. The current price of 15.76 is below the 20-day moving average (MA) of 17.56, below the 50-day MA of 19.93, and above the 200-day MA of 11.67, indicating a neutral trend. The MACD of -0.92 indicates Positive momentum. The RSI at 36.15 is Neutral, neither overbought nor oversold. The STOCH value of 11.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GLUE.

Monte Rosa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLUE	54 Neutral	$1.29B	-33.72	-15.44%	―	1112.27%	―
MNPR	53 Neutral	$392.07M	-42.31	-25.72%	―	―	-73.48%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FULC	49 Neutral	$468.87M	-9.57	-30.25%	―	-100.00%	-305.92%
CTMX	46 Neutral	$813.49M	-33.83	-19.77%	―	-10.26%	144.62%
INBX	42 Neutral	$943.45M	-8.74	-186.06%	―	―	―

Monte Rosa Therapeutics Corporate Events

Monte Rosa Therapeutics Prices $300 Million Public Offering

On January 8, 2026, Monte Rosa Therapeutics priced a $300 million underwritten public offering comprising 11,125,000 shares of common stock at $24.00 per share and pre-funded warrants for 1,375,000 additional shares at $23.9999 per warrant, with underwriters granted a 30-day option to purchase up to 1,875,000 more shares. The deal, sold entirely by the company and expected to close on or about January 12, 2026, should generate approximately $281.6 million in net proceeds, which Monte Rosa plans to use, alongside existing cash and marketable securities, to advance its MRT-8102 program in chronic inflammatory diseases including atherosclerotic cardiovascular disease, further develop and deploy its QuEEN platform for additional molecular glue degraders in immunology, inflammation and oncology, and fund working capital and general corporate purposes; as a result of the capital raise, the company now expects its cash runway to extend into 2029, bolstering its financial position as it progresses three clinical programs and seeks to strengthen its leadership in the emerging MGD therapeutic space.

The most recent analyst rating on (GLUE) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.

Monte Rosa Therapeutics Ends Current ATM Equity Program

Effective January 7, 2026, Monte Rosa Therapeutics, Inc. terminated the sales agreement prospectus tied to its at-the-market equity offering program under its existing registration statement, meaning it will no longer sell common stock under that prospectus unless and until it files new offering documents, while the underlying Sales Agreement with Jefferies LLC remains in force. By the time of the termination, the company had issued and sold 2,955,082 shares of common stock through the program, raising aggregate net proceeds of $24.2 million, signaling a pause in at-the-market equity issuance that could affect its near-term financing flexibility and capital-raising strategy.

The most recent analyst rating on (GLUE) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.

Monte Rosa reports positive Phase 1 data for MRT-8102

On January 7, 2026, Monte Rosa Therapeutics reported positive interim results from a Phase 1 trial of its NEK7-directed molecular glue degrader MRT-8102 in healthy volunteers and subjects with elevated cardiovascular disease (CVD) risk, showing rapid, deep and sustained NEK7 degradation of around 80–90% across single and multiple ascending dose cohorts and in a Part 3 cohort. As of the December 23, 2025 data cutoff, four weeks of MRT-8102 treatment in 24 high‑risk CVD subjects reduced high-sensitivity C-reactive protein (hsCRP) by 85%, with 94% of participants achieving hsCRP levels below 2 mg/L, alongside marked suppression of IL‑1β and IL‑6, including a 55% median IL‑6 reduction in high‑CRP subjects and notable cerebrospinal fluid IL‑6 decreases in two participants, while maintaining a favorable safety profile with only mild to moderate, self-resolving adverse events and no signal of increased infection risk; the strength of these inflammation and biomarker data underpins Monte Rosa’s plans to advance MRT‑8102 into broader development for atherosclerotic cardiovascular disease and other NLRP3/IL‑1/IL‑6‑driven inflammatory conditions, and supports its broader molecular glue degrader pipeline in both immunology and oncology.

The most recent analyst rating on (GLUE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Monte Rosa Therapeutics stock, see the GLUE Stock Forecast page.